Search results for " Risk factor"

showing 10 items of 612 documents

Characterization of chronic obstructive pulmonary disease in dairy farmers

2020

International audience; Background - Although farming is often considered a risk factor for COPD, data regarding the burden and characteristics of COPD in dairy farmers are sparse and conflicting. Objectives - To characterize COPD in dairy farmers. Methods - 4788 subjects entered two parallel COPD screening programs, one in agricultural workers and one in general practice from 2011 to 2015. Subjects with COPD were invited to participate in the characterization phase of the study. Those who accepted were included in two subgroups: dairy farmers with COPD (DF-COPD) (n = 101) and non-farmers with COPD (NF-COPD) (n = 85). Patients with COPD were frequency-matched with subjects with normal spiro…

Occupational risk factorsmedicine.medical_specialtyOrganic dust[SDV]Life Sciences [q-bio]Pulmonary disease010501 environmental sciences01 natural sciencesBiochemistryPulmonary function testing03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineQuality of lifeRisk FactorsInternal medicineOccupational ExposuremedicinePrevalenceHumansEnvironmental risk factors030212 general & internal medicineRisk factorDairy farmingLung function0105 earth and related environmental sciencesGeneral Environmental Science2. Zero hungerCOPDFarmersbusiness.industryChronic obstructive pulmonary diseaseFarmingmedicine.disease3. Good healthrespiratory tract diseasesDairyingSpirometryQuality of LifeOrganic dustbusiness
researchProduct

Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.

2021

International audience; Background: After liver transplantation (LT),de novo malignancies are one of the leading causes of late mortality. The aim of the present retrospective study was to identify the risk factors of de novo malignancies in a large cohort of LT recipients in France, using Fine and Gray competing risks regression analysis.Methods: The study population consisted in 11004 adults transplanted between 2000 and 2013, who had no history of pre-transplant malignancy, except primary liver tumor. A Cox model adapted to the identification of prognostic factors (competitive risks) was used.Results: From the entire cohort, one (or more)de novo malignancy was reported in 1480 L T recipi…

OncologyAdultMalemedicine.medical_specialtyMESH: Liver TransplantationLiver tumormedicine.medical_treatmentLiver transplantationMalignancyPrimary sclerosing cholangitis03 medical and health sciencesLiver disease0302 clinical medicineMESH: Liver NeoplasmsMESH: Risk FactorsRisk FactorsInternal medicinemedicineHumansMESH: IncidenceLung cancerRetrospective StudiesMESH: HumansHepatologybusiness.industryIncidenceLiver NeoplasmsGastroenterologyRetrospective cohort studyMESH: AdultMESH: Retrospective Studies[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyCompeting riskmedicine.disease[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MaleLiver Transplantation030220 oncology & carcinogenesisPopulation study030211 gastroenterology & hepatologybusinessLiver transplantationde novomalignanciesClinics and research in hepatology and gastroenterology
researchProduct

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer

2015

Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index >3% or G3 or Ki67 >20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) …

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentKaplan-Meier EstimateRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyMultivariate AnalysiAdjuvantMastectomyMedicine (all)Hazard ratioEarly breast cancerMiddle AgedTreatment OutcomeItalyOncologyChemotherapy AdjuvantFluorouracilDisease ProgressionFemaleBreast NeoplasmMastectomyHumanmedicine.drugRapidly proliferating tumourAdultmedicine.medical_specialtyTime FactorBreast NeoplasmsDisease-Free SurvivalTime-to-TreatmentAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Italy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Cell Proliferation; Mastectomy; Time-to-Treatment; Cancer Research; Oncology; Medicine (all)Internal medicinemedicineChemotherapyHumansAgedNeoplasm StagingProportional Hazards ModelsCell ProliferationChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryProportional hazards modelRisk FactorAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Cancer Research; OncologyConfidence intervalSurgeryAdjuvant chemotherapyProspective StudieTime to initiation of adjuvant chemotherapyMultivariate AnalysisProportional Hazards ModelMethotrexateNeoplasm Gradingbusiness
researchProduct

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer

2018

Background: Serum levels of neutrophils, platelets, and lymphocytes have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer (BC). Objective: To evaluate the prognostic role of the combination of the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) in patients with high-risk non–muscle-invasive urothelial BC (NIMBC). Design, setting, and participants: A total of 1151 NMIBC patients who underwent first transurethral resection of the bladder tumor (TURBT) at 13 academic institutions between January 1, 2002 and December 31, 2012 were included in this analysis. The median follow-up was 48 mo.…

OncologyMaleBladder cancer; Lymphocyte/monocyte ratio; Neutrophil/lymphocyte ratio; Platelet/lymphocyte ratio; Prognosis; Aged; Biomarkers Tumor; Blood Platelets; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Inflammation; Lymphocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Prognosis; Risk Factors; Urinary Bladder NeoplasmsNeutrophilsmedicine.medical_treatmentLymphocyte:Medicina Básica [Ciências Médicas]Prognosis.030232 urology & nephrologyMonocyteMonocytesSettore MED/24 - Urologia0302 clinical medicineRisk FactorsLymphocytesStage (cooking)Framingham Risk ScoreTumorNeutrophilBladder cancerPrognosis3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisNeutrophil/lymphocyte ratioCiências Médicas::Medicina BásicaDisease ProgressionLymphocyteFemalemedicine.symptomHumanBlood Plateletsmedicine.medical_specialtyPlatelet/lymphocyte ratioPrognosiUrologyInflammationCystectomyFollow-Up StudieCystectomy03 medical and health sciencesInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLymphocyte CountAgedInflammationCarcinoma Transitional CellBladder cancerScience & Technologybusiness.industryProportional hazards modelRisk FactorCarcinomaLymphocyte/monocyte ratioImmunotherapymedicine.diseaseUrinary Bladder NeoplasmsBlood PlateletSurgeryTransitional CellbusinessBiomarkersFollow-Up Studies
researchProduct

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

2017

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malatti…

OncologyMaleCancer ResearchTime FactorsAngiogenesis InhibitorsKaplan-Meier Estimatelaw.invention0302 clinical medicineAutologous stem-cell transplantationMaintenance therapyRandomized controlled triallawRisk FactorsClinical endpointMedicine10. No inequalityLenalidomideAdjuvantMultiple myelomaRandomized Controlled Trials as TopicHematopoietic Stem Cell TransplantationMESH: Angiogenesis Inhibitors/administration & dosageORIGINAL REPORTSMiddle Aged3. Good healthThalidomideAdult; Aged; Angiogenesis Inhibitors; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide; Time Factors; Transplantation Autologous; Treatment Outcome; Young Adult; Stem Cell TransplantationTreatment OutcomeOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisDisease ProgressionMESH: Multiple Myeloma/therapyFemaleMultiple MyelomaAutologousmedicine.drugAdultmedicine.medical_specialtyMESH: Thalidomide/analogs & derivatives[SDV.CAN]Life Sciences [q-bio]/CancerTransplantation AutologousDisease-Free SurvivalDrug Administration ScheduleMaintenance Chemotherapy03 medical and health sciencesYoung AdultInternal medicineChemotherapyHumansLenalidomideAgedTransplantationbusiness.industrymedicine.diseaseThalidomideTransplantationbusiness030215 immunologyStem Cell Transplantation
researchProduct

Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases and risk factors for recurrence in a high prevalence of goiter area

2010

BACKGROUND. Papillary thyroid microcarcinoma (PTMC) is diagnosed with increasing frequency. Since risk factors for an aggressive clinical behavior have not been clearly delineated, the best therapeutic option and follow up protocol for PTMC have not been established yet, especially in case of incidental diagnosis after partial thyroidectomy for benign disease. We reviewed our series of patients with PMTC to determine risk factors for recurrence in a high prevalence of goiter area. METHODS. The medical records of all the patients who underwent total thyroidectomy (TT) with a final pathology report of PTMC between October 2002 and June 2007 were reviewed. Demographic, clinical and pathologica…

OncologyMaleGoiterendocrine system diseasesmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEPapillaryPapillary thyroid cancerRisk Factors80 and overPrevalenceMedicineChildLymph nodeThyroid cancerAged 80 and overGoiterThyroidMiddle AgedPrognosismicrocarcinoma thyroid.medicine.anatomical_structureLocalItalyLymphatic MetastasisThyroidectomyFemaleRadiologyAdultendocrine systemmedicine.medical_specialtyAdolescentInternal medicineCarcinomaHumansNeoplasm InvasivenessThyroid NeoplasmsAgedCompletion thyroidectomyChi-Square Distributionbusiness.industryAdolescent; Adult; Aged; Aged; 80 and over; Carcinoma; Papillary; Chi-Square Distribution; Child; Female; Goiter; Humans; Italy; Linear Models; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence; Local; Prevalence; Prognosis; Risk Factors; Thyroid Neoplasms; ThyroidectomyCarcinomaThyroidectomymedicine.diseaseCarcinoma PapillaryNeoplasm RecurrenceLinear ModelsLymph Node ExcisionSurgeryNeoplasm Recurrence Localbusiness
researchProduct

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

2019

International audience; Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS). Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional g…

OncologyMaleMultifactorial InheritanceLymphomaEpidemiologyChronic lymphocytic leukemiaFollicular lymphomaGenome-wide association studyDiseaseNeurodegenerativemeta-analysiimmune system diseasesHLA AntigensRisk Factorshemic and lymphatic diseases2.1 Biological and endogenous factorsHLA AntigenAetiologyGenetics (clinical)CancerAllele0303 health sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyLymphoma Non-Hodgkinnon-Hodgkin lymphoma030305 genetics & hereditySingle NucleotideHematologyMiddle Aged3. Good healthnon-Hodgkin lymphoma.Public Health and Health ServicesFemaleHumanmedicine.medical_specialtyautoimmune disease; genome-wide association study; meta-analysis; non-Hodgkin lymphoma; Alleles; Autoimmune Diseases; Female; HLA Antigens; Humans; Lymphoma Non-Hodgkin; Male; Middle Aged; Multifactorial Inheritance; Polymorphism Single Nucleotide; Risk Factors; Genetic Predisposition to DiseaseNon-Hodgkinautoimmune diseasePolymorphism Single NucleotideArticleAutoimmune Diseases03 medical and health sciencesRare DiseasesInternal medicineGenetic variationmedicineGeneticsHumansGenetic Predisposition to DiseasePolymorphismAlleles030304 developmental biologyAutoimmune diseasegenome-wide association studybusiness.industryMultiple sclerosisRisk FactorArthritisInflammatory and immune systemHuman Genomemedicine.diseaseLymphomaBrain Disordersmeta-analysisbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Malignancy Risk Models for Oral Lesions

2013

Objectives: The aim of this work was to assess risk habits, clinical and cellular phenotypes and TP53 DNA changes in oral mucosa samples from patients with Oral Potentially Malignant Disorders (OPMD), in order to create models that enable genotypic and phenotypic patterns to be obtained that determine the risk of lesions becoming malignant. Study Design: Clinical phenotypes, family history of cancer and risk habits were collected in clinical histories. TP53 gene mutation and morphometric-morphological features were studied, and multivariate models were applied. Three groups were estabished: a) oral cancer (OC) group (n=10), b) OPMD group (n=10), and c) control group (n=8). Results: An avera…

OncologyMalePathologyGenotypeTP53Family historyYoung adultMouth neoplasmCiencias Médicas y de la SaludAged 80 and overpublic health//purl.org/becyt/ford/3.1 [https]Middle Aged:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludMedicina BásicaUNESCO::CIENCIAS MÉDICASOPMD//purl.org/becyt/ford/3 [https]FemaleMouth NeoplasmsRisk assessmentAdultmedicine.medical_specialtyGenética HumanaContext (language use)OdontologíaMalignancyRisk AssessmentYoung AdultInternal medicinemedicineHumansGeneral DentistryAgedOral Medicine and PathologyModels Statisticalbusiness.industryCancermedicine.diseaseGenes p53Cross-Sectional StudiesOtorhinolaryngologyORAL CANCERTP53; ORAL POTENTIALLY MALIGNANT DISORDERS; RISK FACTORS; GENOTYPE; PHENOTYPEMutationSurgeryResearch-ArticlebusinessMouth DiseasesMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma

2016

Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metas…

OncologyMaleTime FactorsDatabases FactualCancer Treatmentlcsh:MedicinePredictive Value of TestPediatricsBiochemistryGeographical locationsNeoplasms Multiple PrimaryDecision Support Technique0302 clinical medicineInterquartile rangeRetrospective StudieMultiple PrimaryRisk FactorsNeoplasmsMedicine and Health SciencesEthnicitiesPublic and Occupational HealthLiver DiseasesLiver NeoplasmsChild HealthGeneral MedicineMiddle AgedPrognosisItalian PeopleTumor BurdenQuartileOncologyCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisPredictive value of testsCohortPerspectiveHong Kong030211 gastroenterology & hepatologyFemaleSurvival Analysialpha-FetoproteinsHumanBiotechnologymedicine.medical_specialtyCarcinoma HepatocellularAsiaTime FactorSettore MED/12 - GASTROENTEROLOGIAAged; Carcinoma Hepatocellular; Databases Factual; Decision Support Techniques; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms Multiple Primary; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Taiwan; Time Factors; Tumor Burden; alpha-Fetoproteins; Biotechnology; Biochemistry; Molecular Biology; Cell BiologyTaiwanReproducibility of ResultGastroenterology and HepatologyCarcinomasRisk AssessmentDecision Support Techniques03 medical and health sciencesDatabasesDiagnostic MedicinePredictive Value of TestsInternal medicineGastrointestinal TumorsmedicineHumansNeoplasm Invasivenessalpha-FetoproteinMolecular BiologySurvival analysisFactualAgedNeoplasm StagingRetrospective StudiesNeoplasm InvasivenePerformance statusbusiness.industryRisk Factorlcsh:RCarcinomaCancers and NeoplasmsReproducibility of ResultsRetrospective cohort studyHepatocellularHepatocellular CarcinomaCell BiologySurvival AnalysisBCLC StageSurgeryPeople and PlacesPopulation Groupingsbusiness
researchProduct

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective …

2017

Abstract Introduction:Even in the era of novel targeted therapies for the treatment of Chronic Lymphocytic Leukemia (CLL) patients, such as BTK, PI3K and BCL2 inhibitors, allogeneic hematopoietic stem cell transplantations (alloHCT) will remain an important treatment option for a subset of patients with very high risk CLL. The current study focused on the impact of center and procedure-related factors on outcomes after alloHCT, taking into account the impact of patient- and disease-related risk factors. Patients and Methods:Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analyzed. Their data were collected as part of the EBMT CLL Data Quality Initiative. Out…

OncologyMaleTransplantation ConditioningCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Chronic lymphocytic leukemiaMedizinQUALITY MANAGEMENT-SYSTEMKaplan-Meier Estimaterisk factor analysisGUIDELINESBiochemistryallogeneic stem cell transplantation; centre effects; chronic lymphocytic leukaemia; frailties; risk factor analysiscentre effectsTransplantation Conditioning / methods0302 clinical medicineRecurrenceRisk Factorsallogeneic stem cell transplantationLeukemia Lymphocytic Chronic B-Cell / mortalityRegistriesDelivery of Health Care / statistics & numerical dataIBRUTINIBddc:6160303 health sciencesALEMTUZUMABHazard ratioHematopoietic Stem Cell TransplantationProfessional PracticeHematologyMiddle Aged3. Good healthEurope030220 oncology & carcinogenesisABT-199CohortSURVIVALAlemtuzumabFemaleEurope / epidemiologymedicine.drugAdultmedicine.medical_specialtyAllogeneic transplantationImmunologyLower riskDIAGNOSISSettore MED/01 - Statistica Medica03 medical and health sciencesLeukemia Lymphocytic Chronic B-Cell / therapyHematopoietic Stem Cell Transplantation / methodsInternal medicinemedicineHumansKarnofsky Performance Status030304 developmental biologyAgedRetrospective Studiesbusiness.industryProportional hazards modelCHRONIC LYMPHOCYTIC-LEUKEMIARetrospective cohort studySTEM-CELL TRANSPLANTATIONCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryProfessional Practice / statistics & numerical dataTransplantationbusinessDelivery of Health Carefrailtieschronic lymphocytic leukaemia030215 immunologyRESPONSES
researchProduct